Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: edrecolomab, Centocor Inc.

A Abicht1, H Lochmüller

  • 1Genzentrum und Friedrich-Baur-Institut, Ludwig-Maximilians-Universität, Feodor-Lynen-Strasse 25, 81377 München, Germany.

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In response to Gulcin Akinci's and Haluk Topaloglu's letter regarding our article "Predictors of loss of ambulation in Duchenne muscular dystrophy: A systematic review and meta-analysis".

Journal of neuromuscular diseases·2025
Same author

Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.

Journal of neuromuscular diseases·2024
Same author

Factors Associated with Respiratory Health and Function in Duchenne Muscular Dystrophy: A Systematic Review and Evidence Grading.

Journal of neuromuscular diseases·2023
Same author

Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada.

Journal of neuromuscular diseases·2021
Same author

Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.

Journal of neuromuscular diseases·2021
Same author

The Canadian Neuromuscular Disease Registry 2010-2019: A Decade of Facilitating Clinical Research Througha Nationwide, Pan-NeuromuscularDisease Registry.

Journal of neuromuscular diseases·2020
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Edrecolomab, a monoclonal antibody targeting Ep-CAM, shows promise in treating Duke's C colorectal cancer. This therapy offers a favorable side effect profile compared to traditional treatments.

Area of Science:

  • Oncology
  • Immunotherapy
  • Monoclonal Antibody Therapy

Background:

  • Monoclonal antibodies target tumor antigens for specific cancer cell destruction.
  • Edrecolomab is a mouse-derived IgG2A antibody targeting the CO17-1A (Ep-CAM) antigen.
  • It is the first monoclonal antibody approved for cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy of edrecolomab as an adjuvant therapy for Duke's C colorectal cancer.
  • To assess the safety and toxicity profile of edrecolomab compared to conventional therapies.

Main Methods:

  • Clinical trials involving patients with Duke's C colorectal cancer.
  • Adjuvant therapy administration post-surgery.
  • Comparative analysis of side effects and toxicity with radio- and chemotherapy.

Related Experiment Videos

Main Results:

  • Encouraging results reported from clinical trials of edrecolomab.
  • Favorable comparison of side effects and toxicity profiles against conventional treatments.
  • Demonstrated potential as an adjuvant therapy for specific colorectal cancer stages.

Conclusions:

  • Edrecolomab shows significant potential in adjuvant therapy for Duke's C colorectal cancer.
  • The antibody presents a favorable safety profile, offering an alternative to traditional treatments.
  • Further improvements in edrecolomab are needed to benefit more cancer patients.